Barry, OppHub America Desk · · Source: yahoo-tickers-tape-movers
Eli Lilly Stock Eyes Upside on Incretin Drugs, J.P. Morgan Says
* . Morgan's positive assessment of Eli Lilly's (LLY) Zepbound and Mounjaro treatments, coupled with its pipeline, suggests potential upside for investors focused on the obesity-drug market.
Based on reporting from yahoo-tickers-tape-movers.
Eli Lilly (LLY) is poised for further gains in the lucrative obesity-drug market, according to J.P. Morgan. The firm highlighted the potential of Zepbound and Mounjaro, alongside next-generation therapies, as key drivers for future upside. This outlook comes as the pharmaceutical giant continues to expand its footprint in the incretin-based treatment space.
Market context for this story
As of: WeekendLoading quotes…
Informational only — not investment advice. Full markets →
$LLYLilly (Eli)
TradingView
Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView chart — search any symbol in the widget. Confirm on /markets/LLY. Not investment advice.
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
**Implied Volatility / Movement:** NORMAL Eli Lilly (NASDAQ: LLY) is positioned for continued growth within the burgeoning obesity-drug market, driven by its key incretin-based treatments and a robust pipeline of future therapies, J.P. Morgan stated in a recent research note. The investment bank cited Zepbound and Mounjaro, along with upcoming next-generation treatments, as offering multiple avenues for further upside potential for the pharmaceutical company.
### Catalyst Analysis: Analyst Upside View J.P. Morgan's research note suggests a positive outlook for Eli Lilly (NASDAQ: LLY) in the obesity-drug market. The firm's analysts pointed to the company's Zepbound and Mounjaro treatments, as well as its pipeline of next-generation therapies, as providing multiple opportunities for stock appreciation.
## Technical Analysis & Key Risk Watch
292.65 · R1 ## Technical Analysis & Key Risk Watch 271.22 · last ## Technical Analysis & Key Risk Watch 255.40 · S1 ## Technical Analysis & Key Risk Watch 243.23 · S2 ## Technical Analysis & Key Risk Watch 209.53.
Eli Lilly (NASDAQ: LLY) is trading at $1255.40, up 0.88% on the day, with an RSI14 of 69.5. Key levels to watch include resistance at $1271.22 and support at $1243.23. The stock's volume is currently 0.88x its 20-day average.
## Impact on Pharmaceutical Sector The incretin-based drug market represents a significant growth area, and Eli Lilly's strong positioning is noteworthy for investors in the broader pharmaceutical sector. Developments in this area can influence investment flows into companies focused on metabolic and weight-loss treatments.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
OppSHOP
Related to this story
* . Morgan's positive assessment of Eli Lilly's (LLY) Zepbound and Mounj
Shop related →
Investing books
Read the classics
Shop this pick →
Personal finance books
Run the household books
Shop this pick →
Trading notebooks
Write the thesis first
Shop this pick →
Monitor for charts
See every pane
Shop this pick →
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: September 6, 2026 at 8:55 PM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
obesity drugs
Analysts think Eli Lilly will make a lot of money selling popular weight-loss and diabetes drugs. Investors are excited because the company's new medicines could keep growing in popularity.
What changed
J.P. Morgan highlighted Eli Lilly's strong position and pipeline in the booming obesity-drug market.
Who wins / who loses
Eli Lilly and healthcare suppliers win, while alternative weight-loss approaches or competing pharma lags.
Time horizon
Think in terms of the next few months.
Confidence & best fit
medium confidence · Long-term investor
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $LLYBuild slowly — only if it fits your plan
Eli Lilly makes popular weight-loss drugs that people want to buy, which helps the company grow.
View $LLY chart → · End-of-day delayed data
Peer
- $NVOWatch — track, don’t rush
The main rival company that also sells weight-loss drugs and benefits from the same trend.
View $NVO chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Direction: bullish · Style: Debit spread (defined risk) · Level: intermediate
Beginners should skip options because the stock price is high and options can be complicated to set up correctly.
Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Research healthcare real estate trusts leasing facilities to clinical trial operators.
What would break this thesis
- Regulatory setbacks, supply chain disruptions, or weaker-than-expected quarterly sales figures.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.
Based on reporting from yahoo-tickers-tape-movers.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).